# American Vanguard Corp: Form 10-Q for the period ended Sep 30, 2015

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2015-11-03
- Accepted by EDGAR: Nov 3, 2015, 09:58 ET
- Period: 2015-09-30
- Accession: 0001193125-15-363501
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000119312515363501/d192076d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000119312515363501/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-07-01 to 2015-09-30 | $72.5m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2015-01-01 to 2015-09-30 | $205.6m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-07-01 to 2015-09-30 | $41.1m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2015-01-01 to 2015-09-30 | $124.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2015-07-01 to 2015-09-30 | $31.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-01-01 to 2015-09-30 | $81.2m | us-gaap:GrossProfit |
| Operating income | 3 months, 2015-07-01 to 2015-09-30 | $5.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-01-01 to 2015-09-30 | $6.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-07-01 to 2015-09-30 | $700.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2015-01-01 to 2015-09-30 | $2.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-07-01 to 2015-09-30 | $1.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-01-01 to 2015-09-30 | $958.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-07-01 to 2015-09-30 | $2.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-01-01 to 2015-09-30 | $3.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-07-01 to 2015-09-30 | $0.09 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-01-01 to 2015-09-30 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-07-01 to 2015-09-30 | $0.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-01-01 to 2015-09-30 | $0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-07-01 to 2015-09-30 | 29,289,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-01-01 to 2015-09-30 | 29,208,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-01-01 to 2015-09-30 | $51.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2015-01-01 to 2015-09-30 | $36.4m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months, 2015-01-01 to 2015-09-30 | $1.1m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2015-09-30 | $5.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-09-30 | $283.6m | us-gaap:AssetsCurrent |
| Total assets | at 2015-09-30 | $493.9m | us-gaap:Assets |
| Current liabilities | at 2015-09-30 | $114.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-09-30 | $228.5m | us-gaap:Liabilities |
| Long-term debt | at 2015-09-30 | $82.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2015-09-30 | $10.1m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2015-09-30 | $265.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 42,573 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information on risk factors arising during the reporting period, refer to Item 1A., Risk Factors (below). For more detailed information on risk factors affecting the Company generally, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

### RESULTS OF OPERATIONS

### Quarter Ended September 30:

| Net sales: | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Insecticides | $23,539 | $24,626 | $(1,087) |
| Herbicides/soil fumigants/fungicides | 32,682 | 29,363 | 3,319 |
| Other, including plant growth regulators | 7,420 | 10,711 | (3,291) |
| Total crop | 63,641 | 64,700 | (1,059) |
| Non-crop | 8,845 | 6,935 | 1,910 |
|  | $72,486 | $71,635 | $851 |
| Cost of sales: |  |  |  |
| Insecticides | $14,240 | $14,466 | $(226) |
| Herbicides/soil fumigants/fungicides | 17,953 | 17,084 | 869 |
| Other, including plant growth regulators | 4,005 | 7,375 | (3,370) |
| Total crop | 36,198 | 38,925 | (2,727) |
| Non-crop | 4,855 | 4,417 | 438 |
|  | $41,053 | $43,342 | $(2,289) |
| Gross margin: |  |  |  |
| Insecticides | $9,299 | $10,160 | $(861) |
| Herbicides/soil fumigants/fungicides | 14,729 | 12,279 | 2,450 |
| Other, including plant growth regulators | 3,415 | 3,336 | 79 |
| Gross margin crop | 27,443 | 25,775 | 1,668 |
| Gross margin non-crop | 3,990 | 2,518 | 1,472 |
|  | $31,433 | $28,293 | $3,140 |
| Gross margin crop | 43% | 40% |  |
| Gross margin non-crop | 45% | 36% |  |
| Total gross margin | 43% | 40% |  |
|  | **2015** | **2014** | **Change** |
| Net sales: |  |  |  |
| US | $53,167 | $54,552 | $(1,385) |
| International | 19,319 | 17,083 | 2,236 |
|  | $72,486 | $71,635 | $851 |

20

Our overall financial performance for the quarter ended September 30, 2015 reflects the significant improvement in profitability that has been achieved through disciplined manufacturing cost and operating expense management. Our net sales for the period were $72,486, as compared to $71,635 for the third quarter of 2014. Net income attributable to American Vanguard was substantially improved and ended at $2,772, as compared to $732 for the same period in 2014. A more detailed discussion of general market conditions and sales performance by category of products appears below. Net sales for our Crop products were down by approximately 2% at $63,641, as compared to $64,700 posted in the third quarter of 2014. Net sales for Non-Crop products were $8,845, up by about 28% from the comparable prior year period.

Within Crop, net sales of our insecticide products were down about 4% during the third quarter of 2015. Within this group, we recorded strong sales of non-corn products such as Thimet® for peanuts and Counter® for sugar beets. Sales of Mocap® and Nemacur®, sold primarily in international markets, performed well and were up approximately 17% over the prior year. This strong performance included sales recorded following the acquisition of European registrations for Nemacur (announced earlier this year). Our cotton foliar insecticide Bidrin® posted a much lower quarterly performance due to reduced cotton acres in the U.S. this year, lighter pest pressure during the growing season, and some competitive activities. Net sales of our granular soil insecticide products (“GSIs”) are traditionally slow at this time of the year, as the prior growing season has ended and the new selling season typically does not begin until midway through the final quarter of the year. Sales of our leading corn brands of Aztec® and our Force®SmartBox were somewhat below last year.

Within our herbicides/soil fumigants /fungicides products, net sales for the third quarter of 2015 increased by approximately 10% to $32,682, over the comparable period of 2014. This improved performance was driven by higher sales of our post-emergent corn herbicide, Impact®, and flat sales of our non-corn herbicide, Dacthal®. In addition, included in this category were some initial sales of our newly acquired international herbicide, Hyvar/Krovar. Finally, sales of our market leading soil fumigant were up 5%, as compared to sales in the same period of the prior year.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales decreased by about 31%, as compared to those in the third quarter of 2014. This decrease was driven by lower sales of our cotton harvest defoliant, Folex®, due to reduced U.S. cotton acreage in 2015 and unfavorable autumn harvest weather conditions. We also recorded lower toll manufacturing sales in the current quarter relative to the same period last year, due to changes in the timing of our production schedule, which resulted in sales occurring earlier this year in the three months ended June 30, 2015, rather than in the current quarter.

The non-crop portion of our business ended the third quarter of 2015 at $8,845, a 28% increase, as compared to $6,935 for the same period of the prior year. This change was due largely to significantly increased domestic sales of our mosquito control adulticide, Dibrom®, partially offset by declines in year-over-year sales of our Pest Strip products for commercial pest control and Envance natural oil-based products for consumer pest control.

Our international business continued to perform well during the three months ended September 30, 2015 with net sales of $19,319 which was a 13% improvement as compared to the same period of the prior year. Sales for the quarter benefited from initial sales of our two newly acquired product lines – European Nemacur and the Hyvar/Krovar products. The Company announced these international product acquisitions earlier this year. In addition, the Company recorded stronger sales for Counter and Dacthal as compared to same period of last year.

Our cost of sales for the third quarter of 2015 was $41,053 or 57% of net sales. This compared to $43,342 or 60% of net sales for 2014. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. During the three month periods ended September 30, 2015 and 2014, raw material purchase prices remained essentially flat. As a percentage of sales, raw materials increased from 40% in 2014 to 41% in 2015. This increase was driven by the increased proportion of international sales, which represented 27% of sales in the quarter ended September 30, 2015 and 24% in the comparable quarter of prior year. Labor and burden costs also increase from 13.2% in 2014 to 13.7% in 2015. This effect was driven by the shift from domestic to international sales and the mix of product sales.

Furthermore, our cost of sales includes the impact of unabsorbed factory costs. In the third quarter of 2015 this amounted to 2% of sales, whereas in the same period of the prior year unabsorbed factory costs were 8% of sales. This improved performance was generated by the impact of cost controls including the reduction in headcount at the end of 2014 and the benefit of increased factory activity as we manage the demand and manufacturing supply position. Overall this improvement added $4,218 to our gross profit performance in the third quarter of 2015, as compared to this time last year.

Finally, within gross profit it should be noted that following the Company’s product line acquisitions announced earlier this year, some sales are being managed by the selling entities for an interim period due to conditions that were known to the Company prior to closing, such as the administrative task of transferring certain registrations to the Company. During this interim period, the Company will earn royalties on those sales and record the associated income as revenue. Treating the income in this manner increased gross margin reported this quarter by approximately 1%.

As a result, our gross profit ended at $31,433 and 43% of sales, as compared to $28,293 and 40% last year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses decreased by $1,308 to $26,059 for the three months ended September 30, 2015, as compared to the same period in 2014. The differences in operating expenses by department are as follows:

|  | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Selling | $6,493 | $7,067 | $(574) |
| General and administrative | 6,980 | 7,354 | (374) |
| Research, product development and regulatory | 4,494 | 5,200 | (706) |
| Freight, delivery and warehousing | 8,092 | 7,746 | 346 |
|  | $26,059 | $27,367 | $(1,308) |

- Selling expenses decreased by approximately 8%, as compared to the same quarter of the prior year. The main drivers for the decrease are lower travel costs for the field sales team and reduced costs for outside services in support of advertising and field stewardship activities.
- General and administrative expenses decreased by 5% quarter over quarter. The main drivers for the decrease are primarily due to lower incentive compensation costs and legal costs. This was offset by an increase in amortization expense from the product line acquisitions completed during the early part of 2015.
- Research, product development costs and regulatory expenses decreased by about 14% over the comparable three month period of the prior year. This was driven by timing of product development studies and as a result of a one-time benefit from the consolidation of two industry wide task force groups.
- Freight, delivery and warehousing costs increased by about 4%, driven primarily by slightly higher sales including higher sales of our high volume fumigants and increased international sales following the acquisitions completed earlier in the year. As a percentage of sales, freight ended at 11% of sales for the three months ended September 30, 2015, which was consistent with the same period of the prior year.

Interest costs, net of capitalized interest, were $638 in the three months to September 30, 2015 as compared to $779 in the same period of 2014. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Q3 2015 Average Debt | Interest Expense | Interest Rate | Q3 2014 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Average revolving line of credit | $88,826 | $498 | 2.2% | $94,935 | $613 | 2.6% |
| Notes payable | 10,081 | 101 | — | 152 | 1 | — |
| Amortization of deferred loan fees | — | 62 | — | — | 106 | — |
| Amortization of other deferred liabilities | — | 29 | — | — | 74 | — |
| Other interest expense | — | 10 | — | — | 10 | — |
| Subtotal | $98,907 | $700 | 2.8% | $95,087 | $804 | 3.4% |
| Capitalized interest | — | (62) | — | — | (25) | — |
| Total | $98,907 | $638 | 2.6% | $95,087 | $779 | 3.3% |

The Company’s average overall debt for the three months ended September 30, 2015 was $98,907, as compared to $95,087 for the three months ended September 30, 2014. Included in interest expense of $638 during the three months ended September 30, 2015, are non-cash costs related to amortization of discounting for deferred payments and other interest expense, net of capitalized interest, in the amount of $140 as compared to $166 for the same period of the prior year. The effective rate on our bank borrowings was 2.2% for the period to September 30, 2015, as compared to 2.6% for the same period of the prior year. Our overall effective interest rate was 2.6% for the three months ended September 30, 2015, as compared to 3.3% at September 30, 2014.

Income tax expense totaled $1,643 for the three months ended September 30, 2015. The effective tax rate for the quarter was 34.7%. There was no tax expense for the three months ended September 30, 2014. The comparatively higher rate is a result of an improvement in domestic performance (which bears a higher tax rate) in the third quarter of 2015 compared to the same period of 2014. This has caused us to modify our forecast for the full year performance and, as a result adjusted the forecasted rate for the full year of 2015, which impacts the quarter. Our estimate of the full year income tax rate is subject to ongoing review and revision.

Our overall net income for the three months ended September 30, 2015 increased to $2,772 or $0.09 per diluted share as compared to $732 or $0.03 per diluted share in the same quarter of 2014.

### Nine Months Ended September 30:

| Net sales: | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Insecticides | $85,484 | $105,587 | $(20,103) |
| Herbicides/soil fumigants/fungicides | 71,973 | 66,220 | 5,753 |
| Other, including plant growth regulators | 23,497 | 23,447 | 50 |
| Total crop | 180,954 | 195,254 | (14,300) |
| Non-crop | 24,620 | 25,789 | (1,169) |
|  | $205,574 | $221,043 | $(15,469) |
| Cost of goods sold: |  |  |  |
| Insecticides | $55,244 | $66,117 | $(10,873) |
| Herbicides/soil fumigants/fungicides | 41,139 | 39,490 | 1,649 |
| Other, including plant growth regulators | 14,372 | 16,899 | (2,527) |
| Total crop | 110,755 | 122,506 | (11,751) |
| Non-crop | 13,615 | 15,279 | (1,664) |
|  | $124,370 | $137,785 | $(13,415) |
| Gross margin: |  |  |  |
| Insecticides | $30,240 | $39,470 | $(9,230) |
| Herbicides/soil fumigants/fungicides | 30,834 | 26,730 | 4,104 |
| Other, including plant growth regulators | 9,125 | 6,548 | 2,577 |
| Gross margin crop | 70,199 | 72,748 | (2,549) |
| Gross margin non-crop | 11,005 | 10,510 | 495 |
|  | $81,204 | $83,258 | $(2,054) |
| Gross margin crop | 39% | 37% |  |
| Gross margin non-crop | 45% | 41% |  |
| Total gross margin | 40% | 38% |  |
|  | **2015** | **2014** | **Change** |
| Net sales: |  |  |  |
| US | $146,231 | $162,602 | $(16,371) |
| International | 59,343 | 58,441 | 902 |
|  | $205,574 | $221,043 | $(15,469) |

23

Overall financial performance was mixed for the nine month period ended September 30, 2015 with net sales down approximately 7% and net income up approximately 33%, as compared to the same period of 2014.

Net sales for the nine month period ended at $205,574 compared to $221,043 in 2014. With respect to specific categories, net sales for our crop business were $180,954, down by approximately 7% from $195,254 in 2014, while net sales for non-crop products were $24,620, down by about 4% from $25,789, in the comparable period of the prior year. Our international sales are slightly ahead year to date at $59,343, as compared to $58,441 for the same period of the prior year, which is an improvement of 2%. A more detailed discussion of general market conditions and sales performance by category of products appears below.

As has been noted in previous filings, procurement patterns in the Midwest corn market have been negatively influenced by the excess inventories that accumulated in the distribution channel. As a consequence, restocking orders for our corn products during 2015 were lower than in periods prior to the inventory build-up, as customers continued to draw down carryover inventories. As we close out the 2014-15 growing season we believe that channel inventory levels are significantly reduced in comparison to the start of the year. However, there may be further channel inventory reduction that impacts the new season. We have also experienced a difficult year for our cotton products, as a reduction in planted acres, lower foliar pest pressure, and some unfavorable weather conditions have trimmed demand. In most of the other crops that we serve, such as potatoes, peanuts, various fruit and vegetable crops, our product sales are performing at a level comparable to that of the same period in the prior year.

Net sales of our insecticides as a group were down about 19% at $85,484, during the first nine months of 2015, as compared to $105,587 during the same period of the prior year. Within these products, net sales of our granular soil insecticides (“GSIs”) were down approximately 8% from the comparable period in 2014. Our primary corn soil insecticides Aztec® and Force SmartBox® experienced significant declines reflecting the Midwest distribution channel inventory drawdown. Thimet®, used in peanuts and sugarcane, saw a modest year-over-year sales decrease, while Counter, used in corn and sugar beets posted a modest sales increase. Mocap® and Nemacur®, products that are largely sold in international markets, together posted marginally increased sales for the YTD period. Net sales of our non-GSI insecticides declined by approximately 37%, during the first nine months of 2015, mainly due to lower year-over-year sales of Bidrin® our foliar cotton insecticide which suffered from lower U.S. cotton acreage and low pest pressure.

Within the group of herbicides/fungicides/fumigants, net sales for the first three quarters of 2015 rose by 8%, as compared to the first nine months of 2014. The main driver of this category has been the solid demand for our soil fumigants which rose more than 11% during the first nine months of the 2015, despite some challenging Western U.S. drought conditions. This increase was helped by slight sales gains in our existing herbicide products Impact® and Dacthal®. Finally, included are sales of our herbicide Hyvar/Krovar, which we acquired earlier this year.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales were flat with gains on Metaldehyde products, our SmartBlock potato sprout inhibitor and toll manufacturing offset by declines on Folex® and NAA.

Our international sales were comparatively flat for the nine month period ended September 30, 2015 at $59,343 which was a 2% improvement as compared to the same period of the prior year. Sales benefited from initial sales of our two newly acquired product lines – European Nemacur and the Hyvar/Krovar products. The Company announced these international product acquisitions earlier this year. In addition we experienced reduced sales of our nematicides during first half of the year as result of missing out on an annual contract with one customer in Central America.

Our non-crop sales for the first nine months of 2015 were $24,620, as compared to $25,789 for the same period of the prior year. In these sales, our mosquito adulticide Dibrom® was up strongly due in part to increased storm conditions in the southern U.S, offset by sales of our Pest strip products which were down in comparison to the same period of 2014.

Our cost of sales for the first nine months of 2015 was $124,370 or 60% of net sales, compared to $137,785 or 62% of net sales for 2014. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. During the nine months ended September 30, 2015, raw material purchase prices reduced by 1.3%. During the nine month period of the prior year raw material prices remained flat. As a percentage of sales, material costs increased to 40% in 2015, as compared to 39% in 2014. This was driven by the increase in international sales to 29% of sales for the nine months ended September 30, 2015, from 26% for comparable period of the prior year. Offsetting the increase in raw material cost of sales, factory costs increased from 13.2% in 2014 to 13.7% in 2015. This was primarily driven change in balance of international sales and domestic sales – in 2015 we have 29% international sales as compared to 26% in 2014. International sales tend to face more generic competition, and generate lower gross margins (and consequently higher relative cost of sales). Furthermore, we have some different mix and volume impacts domestically which accounts for the balance.

Furthermore, our cost of sales includes the impact of unabsorbed factory costs. In the first nine months of 2015 this amounted to 5% of sales, whereas in the same period of the prior year unabsorbed factory costs were 9% of sales. This improved performance was generated by the impact of cost controls including the reduction in headcount at the end of 2014 and the benefit of increased factory activity as we manage the demand and manufacturing supply position. Overall this improvement added $9,664 to our gross profit performance for the nine month period and substantially mitigated the impact of lower sales revenues on gross margin, discussed above. As a result, our gross profit ended at $81,204 and 40% of sales, as compared to $83,258 and 38% last year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses decreased by $3,578 to $74,325 for the nine months ended September 30, 2015, as compared to the same period of 2014. The differences in operating expenses by department are as follows:

|  | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Selling | $20,803 | $24,043 | $(3,240) |
| General and administrative | 20,389 | 20,152 | 237 |
| Research, product development and regulatory | 14,606 | 14,973 | (367) |
| Freight, delivery and warehousing | 18,527 | 18,735 | (208) |
|  | $74,325 | $77,903 | $(3,578) |

- Selling expenses for the period decreased by about 13% over the comparable period. The main drivers for the decrease are lower advertising and promotional activities, reduced levels of temporary employees reflecting improving efficiency in the sales and marketing teams and reductions in office expenses primarily for our international sales locations.
- General and administrative expenses increased by about 1% over the same period of 2014. The main drivers for the increase are amortization expense on product line acquisitions completed during the current year and a small increase in incentive compensation costs, offset by lower legal costs.
- Research, product development costs and regulatory expenses decreased by about 2% when compared to the same period of 2014. This is as a result of delayed spending on product development studies, offset by continued work focused on long-term business development projects. Furthermore, our regulatory compliance costs are tracking below last year and benefited from the consolidation of two industry wide task force groups.
- Freight, delivery and warehousing costs for the nine months ended September 30, 2015 were $18,527 or 9% of sales as compared to $18,735 or 8.4% of sales for the same period in 2014. As a percentage of sales, freight costs rose during the period due proportionately higher sales of products having greater costs including soil fumigants and international goods.

Interest costs net of capitalized interest, were $1,941 in the nine months of 2015, as compared to $2,236 in the same period of 2014. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Nine months ended September 30, 2015 Average Debt | Interest Expense | Interest Rate | Nine months ended September 30, 2014 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Average revolving line of credit | $100,292 | $1,541 | 2.0% | $94,135 | $1,786 | 2.5% |
| Notes payable | 5,834 | 170 | — | 169 | 4 | — |
| Interest Income | — | (1) | — | — | — | — |
| Amortization of deferred loan fees | — | 228 | — | — | 223 | — |
| Amortization of other deferred liabilities | — | 114 | — | — | 248 | — |
| Other interest expense | — | 38 | — | — | 31 | — |
| Subtotal | $106,126 | $2,090 | 2.6% | $94,304 | $2,292 | 3.2% |
| Capitalized interest | — | (149) | — | — | (56) | — |
| Total | $106,126 | $1,941 | 2.4% | $94,304 | $2,236 | 3.2% |

The Company’s average overall debt for the nine months ended September 30, 2015 was $106,126 as compared to $94,304 for the same period of 2014. The increase is due primarily to borrowing associated with two product line acquisitions during the reporting period. Included in interest expense of $1,941 during the nine months ended September 30, 2015, are non-cash costs related to amortization of discounting of deferred payments and other interest expense in the amount of $400 as compared to $450 for the same period of the prior year. The effective rate on our bank borrowings was 2.0% for the period to September 30, 2015, as compared to 2.5% for the same period of the prior year. Our overall effective interest rate was 2.4% for the nine months ended September 30, 2015, as compared to 3.2% in the same period of 2014.

Income tax expense increased by $102 to end at $958 for the nine months ended September 30, 2015, as compared to $856 for the comparable period in 2014. The effective tax rate for the nine months ended September 30, 2015 is 19%, as compared to 21% in the same period of the prior year. The reduction in the rate is primarily driven by the ratio of projected domestic sourced income in relation to foreign sourced income, wherein comparatively higher earnings in our international tax jurisdictions tare taxed at a comparatively lower rate than the U.S. statutory rates. The tax rate is based on management’s estimate of the full year income tax rate and is subject to ongoing review and revision.

Our overall net income attributable to American Vanguard for the nine months of 2015 was $3,604 or $0.12 per diluted share, as compared to $3,036 or $0.11 per diluted share in the same period of 2014.

#### LIQUIDITY AND CAPITAL RESOURCES

The Company generated $51,807 of cash in operating activities during the nine months ended September 30, 2015. This compared to $33,836 of cash used in the same period of last year. Net income of $3,400, non-cash depreciation, amortization of intangibles, other assets and discounted future liabilities in the amount of $16,300, stock based compensation expense of $2,935 plus a non cash loss recorded on our equity investment provided a net cash inflow of $23,215 as compared to $21,623 for the same period last year.

Accounts receivables ended at $89,723, as compared to $86,027 at December 31, 2014. This increase in trade receivables of $3,696 is the result of the timing of cash collection. In addition, other receivables increased by $2,476 primarily related to Value Added Tax (“VAT”) of $2,100 that we expect to recover during the final quarter of 2015.

Our inventories have reduced by $4,135 during the first nine months of 2015, as compared to increasing by $31,690 during the same period of the prior year. This 2015 performance reflects the efforts that the Company has put into controlling the balance of manufacturing and demand while continuing to correct channel inventory levels. As of the balance sheet date, September 30, 2015, we believe our inventories are valued at lower of cost or market.

During the nine months ended September 30, 2015, deferred revenues decreased by $860, as compared to a decrease of $2,769 for the same period of the prior year. The decrease in deferred revenues reflects individual customer decisions to take up related incentive programs and pay in advance for product deliveries later in the growing season.

The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th each year. During the nine months ended September 30, 2015, the Company made accruals in the amount of $38,102. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. However, there are some programs that are paid more frequently or that have different settlement dates that reflect particular growing seasons. During the first nine months of 2015, the Company made payments in the amount of $17,120. Payments are not generally significant in the second and third quarters of each financial year. During the nine months ended September 30, 2014, the Company accrued $36,080 and made payments in the amount of $16,980.

Our prepaid and other assets were reduced by $1,143 primarily related to sales of SmartBox controllers. Tax receivable decreased by $4,739 as a result of receiving the federal corporate income tax refund for 2014. Accounts payable increased by $3,010, primarily as a result of a comparatively strong manufacturing quarter and accrued expenses increased by $1,147. In aggregate, this amounted to an inflow of $10,039. During the same period of 2014, these items amounted to an outflow of $22,739.

The Company is working to manage its capital spending closely during this slow trading period and utilized $5,196 during the nine months ended September 30, 2015, compared to utilizing $5,947 during the same period of 2014. This is primarily driven by capital spending in our factories. Also during the first nine months of 2015, the Company completed two acquisitions of product lines and spent a total of $36,435 on those transactions (including $300 on an immaterial purchase). Furthermore, the Company increased its ownership share of its Envance subsidiary by paying $125 to its joint venture partner TyraTech. There were no investments or intangible asset purchases in the same period of the prior year.

Financing activities used $8,251 during the nine months ended September 30, 2015, compared to providing $38,476 in the same period of the prior year. This included a pay down of $16,000 against our senior credit facility, in addition to the increase in deferred loan fees of $120. During the period we increased our other notes payable in the amount of $10,000 related to one product line acquisition and made $1,252 deferred payments related to product acquisitions. Further, the Company made dividend payments in the amount of $1,141. Finally, the Company utilized $311 (including associated tax benefits from the exercise of stock options of $8) upon vesting of shares and the exercise of stock options and received $573 from the sale of common stock under its Employee Stock Purchase Plan as compared to receiving $1,616 during the first nine months of 2014.

The Company has a revolving line of credit and a note payable that together constitute the short-term and long-term loan balances shown in the balance sheets at September 30, 2015 and December 31, 2014. These are summarized in the following table:

| Indebtedness $000’s | September 30, 2015 Long- term | Short- term | Total | December 31, 2014 Long- term | Short- term | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit | $83,400 | $— | $83,400 | $99,400 | $— | $99,400 |
| Deferred loan fees | (742) | — | (742) | (850) | — | (850) |
| Notes payable | — | 10,073 | 10,073 | 55 | 71 | 126 |
| Total Indebtedness | $82,658 | $10,073 | $92,731 | $98,605 | $71 | $98,676 |

The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio (taking into account the Company’s twelve month trailing EBITDA), (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of September 30, 2015 the Company met all covenants in that credit facility.

At September 30, 2015, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $40,189 under the credit facility agreement. This compares to an available borrowing capacity of $51,156 as of September 30, 2014. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, has improved, (2) borrowings have decreased notwithstanding the product line acquisitions completed in the second quarter of 2015 and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement) is lower when compared with the earlier period.

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

In September 2015, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, *Business Combination (Topic 805):Simplifying the Accounting for Measurement Period Adjustments.* Current GAAP requires that during the measurement period, the acquirer retrospectively adjust the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Those adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The acquirer also must revise comparative information for prior periods presented in financial statements as needed, including revising depreciation, amortization, or other income effects as a result of changes made to provisional amounts. This amendment eliminates the requirement to retrospectively account for those adjustments and recognize adjustments in the reporting period in which they are determined. Furthermore, the amendment to this update would require disclosure (either on the face of the income statement or in the notes) of the nature and amount of the measurement period adjustments recognized in the current period including the portion of the amount recorded in current-period income by line item that would have been recorded in previous reporting periods if the adjustment to the balance sheet amounts had been recognized as of the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years, with early adoption permitted. Upon adoption, the Company will follow the guidance in this ASU when applying Topic 805.

In July 2015, FASB issued ASU2015-11, *Inventory (Topic 330)*. Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost. This update is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company will evaluate the impact of this adoption for fiscal year 2016.

In April 2015, FASB issued ASU 2015-03, *Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.* This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. ASU 2015-03 is effective for financials statement issued for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company evaluated the impact and has elected an early adoption of this update in the quarter ended June 30, 2015. This change was immaterial to the condensed consolidated financial statements.

In August 2014, FASB issued ASU 2014-15, *Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.* This ASU requires that management of an entity assesses whether there is substantial doubt about the ability of the entity to continue as a going concern and for making the appropriate disclosures. The assessment must be performed at each annual and interim reporting period, and under ASU 2014-15, there is substantial doubt about an entity’s ability to continue as a going concern if it is probable that the entity will be unable to meet its obligations as they become due within 12 months of the date of the financial statements are issued. In the assessment, management must consider the information available at the date of issuance of the financial statements, as well as mitigating factors and plans to alleviate the substantial doubt. ASU 2014-15 is effective for annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. Upon adoption, the Company will follow the guidance in this ASU when assessing going concern.

In June 2014, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-12, *Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force*. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers*. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). In April 2015, the FASB voted to defer the effective date of this update to December 15, 2017. The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and has not yet determined the method by which we will adopt the standard in 2018 or its impact on our consolidated financial statements.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2014, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2014.

## Market risk

As filed, 1,252 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2014.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,077 characters.

As of September 30, 2015, the Company has established a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of September 30, 2015, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 2,347 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2014, filed on February 27, 2015. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

In the course of preparing this Form 10-Q for the three and nine month period ended September 30, 2015, we have identified the following specific business risk related to recent regulatory activities in the United States:

On September 25, 2015 the United States Environmental Protection Agency (“USEPA”) published in the Federal Register draft human health risk assessments for four of the Company’s organophosphate (“OP”) compounds (marketed under the names Bidrin, Counter, Folex and Mocap) in which it recommends the application of a 10X safety factor under the FQPA (Food Quality Protection Act) in light of the alleged possibility of neurodevelopmental harm to women and children based on epidemiological data. The agency is seeking public comment on these risk assessments not later than November 25, 2015 and has indicated its current intention to apply this safety factor to all registered OPs, as they come up for review or renewal. There are at least 10 other companies that have OP products which are sold (and used) in the U.S. The Company, like many in our industry, believes that the basis for applying this safety factor is unsound and that there is no causal link between the perceived harm and the use of its products. Accordingly, the Company intends to take all action necessary to defend its registrations. It is expected we will be joined in this effort by other companies who are similarly concerned about the potential impact of EPA’s action. However, in the short term, it is likely that USEPA’s current position will limit the Company’s ability to expand labeled uses of its OPs. Further, there is no guarantee that the Company’s actions will alter the course that USEPA has proposed and, if the agency’s position becomes final, some uses of the company’s OP products could be limited or cancelled. Such action could have an adverse effect upon the Company’s financial performance in future reporting periods.

Filed Nov 3, 2015.
Source: SEC EDGAR, the filing index for accession 0001193125-15-363501. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
